Crossmark

474 First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0474

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Obeidat, Akram

Atieh, Anas

Vitenshtein, Alon

Cinamon, Guy

Paz, Keren

Roviš, Tihana

Brilc, Paola

Hirsl, Lea

Mandelboim, Ofer

Jonjic, Stipan

Tsukerman, Pini
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05378425 at ClinicalTrials.gov

Documents that mention this clinical trial

474 First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity
https://doi.org/10.1136/jitc-2022-sitc2022.0474